Santen today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the ...

An exclusive program uniting the top 12% of U.S. MiSight day prescribers to advance myopia management strategies.

The Nexperia case offers a sobering tale for the future of European technological competitiveness.

Over time, as the Bush administration sank into ignominy, Cheney’s influence waned. He left office one of its most reviled ...

The US launch of a myopia control spectacle lens, research into modifiable myopia risk factors, and atropine developments ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SYD-101 met its primary phase 3 efficacy endpoint, but ...

In a survey of U.S. optometrists, practice owners and managers, about one-third of those not offering myopia management say it is primarily because they lack the expertise to do so, according to a ...

Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...

UAB School of Optometry professor is joining a national network study to research myopia prevention in children. Myopia, commonly known as nearsightedness, is a global epidemic that affects over 2 ...

Submitted data were not enough to support the effectiveness of SYD-101 in children with myopia, according to the FDA. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) ...

Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025 ...

Essilorluxottica (OTC) ((ESLOY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...